Market Access News | pharmaphorum

News

CSL, Arcturus get first approval for self-assembling RNA jab

Japan’s medicines regulator has approved the first vaccine based on self-assembling RNA, a spin on the mRNA technology used in current shots, which is designed to deliver greater effi

News

FDA okays first therapy for desmoid tumours from SpringWorks

Pfizer spin-out SpringWorks Therapeutics has its first approved product after getting a green light from the FDA for Ogsiveo, the first-ever therapy for a rare type of non

News

Lifeline for Wolman disease kids as NICE backs Alexion drug

Infants with a rare and fatal congenital disorder called Wolman disease in England and Wales will soon have access to a new drug via the NHS that can dramatically extend t

News

Dupixent aces second COPD study, setting up FDA filing

With a second positive phase 3 trial in hand, Sanofi and Regeneron have said they plan to file for approval of Dupixent in chronic obstructive pulmonary disease (COPD), a

News

Abecma delay gives Carvykti a chance to catch up

Bristol-Myers Squibb and partner 2seventy bio are facing a delay in their attempt to bring BCMA-directed CAR-T therapy Abecma to the US market as an earlier-line therapy f

News

Generics group says VPAG may lead to shortages

Among those celebrating today’s agreement on a voluntary rebate scheme for branded medicines in the UK, there are dissenting voices, including a group representing manufac

CSL, Arcturus get first approval for self-assembling RNA jab

FDA okays first therapy for desmoid tumours from SpringWorks

Lifeline for Wolman disease kids as NICE backs Alexion drug

Dupixent aces second COPD study, setting up FDA filing

Abecma delay gives Carvykti a chance to catch up

Generics group says VPAG may lead to shortages

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks